2019 Abstracts

Ordinary Submission – PACTRIMS 2019

Poster Number Topic Abstract Title Author Country
P-1 MS: Epidemilogy, Clinical Study and Care Prevalences and incidences of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea Jee Eun Kim Republic of Korea
P-2 MS: Epidemilogy, Clinical Study and Care Prevalence of NMOSD and MS in the Indigenous Populations of Australia and New Zealand Simon Broadley Australia
P-3 MS: Epidemilogy, Clinical Study and Care A Single-center Retrospective Analysis of Clinical Epidemiology of Multiple Sclerosis  Jingqi Wang China
P-4 MS: Epidemilogy, Clinical Study and Care Nationwide Trends in Epidemiology and Treatment Patterns of Multiple Sclerosis in Taiwan, 2007-2016 Long-Sun Ro Taiwan
P-5 MS: Epidemilogy, Clinical Study and Care Treatment patterns of patients with multiple sclerosis in China: A single-center experience Rui Li China
P-6 MS: Epidemilogy, Clinical Study and Care Comparison of Multiple Sclerosis Patients Using First Line Treatment vs Second Line Treatment Nilda Turgut Turkey
P-7 MS: Epidemilogy, Clinical Study and Care Exploration of factors which influence treatment decisions of patients with Multiple Sclerosis Belinda Bardsley Australia
P-8 MS: Epidemilogy, Clinical Study and Care Early Treatment in Clinically Isolated Syndrome to Decrease Relapse Rate Wookyo Jeong Republic of Korea
P-9 MS: Epidemilogy, Clinical Study and Care Access and barriers to Multiple Sclerosis Disease Modifying Therapies in a Tertiary Center in Singapore Siew Noi Janis Tye Singapore
P-10 MS: Epidemilogy, Clinical Study and Care Clinical Spectrum of Multiple Sclerosis at Hasan Sadikin Hospital Bandung Feby Purnama Indonesia
P-11 MS: Epidemilogy, Clinical Study and Care Overlap Syndrome in Central Nervous System Demyelinating Diseases Jie Ping Schee Malaysia
P-12 MS: Epidemilogy, Clinical Study and Care Pure spinal multiple sclerosis: A possible novel entity within the Multiple Sclerosis disease spectrum Jie Ping Schee Malaysia
P-13 MS: Epidemilogy, Clinical Study and Care The disease course of multiple sclerosis without disease modifying drug in Japan Katsuichi Miyamoto Japan
P-14 MS: Epidemilogy, Clinical Study and Care Current Healthcare Situation of Patients with Multiple Sclerosis in Japan Based on Retrospective Claims Database Analysis: Trend over the Disease Course Hiromichi Otaka Japan
P-15 MS: Epidemilogy, Clinical Study and Care Using AAN MS Quality Measures to Assess and Improve Care of Multiple Sclerosis Patients in Singapore Xue Juan Peng Singapore
P-16 MS: Epidemilogy, Clinical Study and Care Coming of Age – our experience of transiting the care for paediatric Multiple Sclerosis patients to an adult service Sing Yee Hoh Singapore
P-17 MS: Epidemilogy, Clinical Study and Care Longitudinal electronic patient-reported outcome collection in a treated relapsing multiple sclerosis cohort: Comparison with clinical, cognitive and quantitative magnetic resonance imaging metrics Heidi Beadnall Australia
P-18 MS: Epidemilogy, Clinical Study and Care Self-reported quality of life in multiple sclerosis (MS) and neuromyelitis optica spectrum disease (NMOSD) patients in a single center in Korea Hye Jung Lee Republic of Korea
P-20 MS: Epidemilogy, Clinical Study and Care Cognitive Performance and Clinical Profiles of Relapsing and Progressive Multiple Sclerosis Patients in Hong Kong Alexander, Yuk Lun Lau China
P-21 MS: Epidemilogy, Clinical Study and Care Cognitive Status may Predict Physical Disability Change over a 3-Year Period in Japanese Patients with Multiple Sclerosis Masaaki Niino Japan
P-23 MS: Epidemilogy, Clinical Study and Care Vitamin D Deficiency and its Association with Fatigue and Quality of Life in Multiple Sclerosis Patients Yesim Beckmann Turkey
P-24 MS: Epidemilogy, Clinical Study and Care Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Comparison of Oxidative Burden and Vitamin D Levels Gayathree Nayanajeehwi Sri Lanka
P-26 MS: Epidemilogy, Clinical Study and Care Corneal Confocal Microscopy: A Rapid Non-Invasive Surrogate Endpoint for Axonal Loss in Multiple Sclerosis Saadat Kamran Qatar
P-27 MS: Laboratory Study Cellular Immunity in Central Nervous System During Acute Flare-ups in Patients with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorders Makoto Matsui Japan
P-28 MS: Laboratory Study Reciprocal Alteration of Circulating T Follicular Helper Cells and Regulatory T Follicular Cells in Patient with Multiple Sclerosis Razaul Haque Republic of Korea
P-29 MS: Laboratory Study Narrowband UVB Phototherapy Alters Peripheral Blood Immune Cell Frequencies In People With Clinically Isolated Syndrome Stephanie Trend Australia
P-30 MS: Laboratory Study Distinct distribution pattern of microglia and macrophages in concentric lesions of Baló’s disease and neuromyelitis optica spectrum disorders: with special reference to lamellar configuration Katsuhisa Masaki Japan
P-31 MS: Laboratory Study Anti-JC virus antibodies in Korean patients with multiple sclerosis Juhyeon Kim Republic of Korea
P-32 MS: Laboratory Study Disease-characteristic TCRs recognize CMV in Japanese MS with HLA-DRB1*04:05; a novel approach with GLIPH Fumie Hayashi Japan
P-33 MS: Laboratory Study Increase of EBV lytic infection in Japanese patients with multiple sclerosis Noriko Isobe Japan
P-34 MS: Laboratory Study Cytokines in First-Onset of Neuromyelitis Optica Spectrum Disorders and Clinically Isolated Syndrome Linlin Yin China
P-35 MS: Laboratory Study Plasma Copeptin Levels In Patients With Multiple Sclerosis Mesrure Koseoglu Turkey
P-36 MS: Laboratory Study Serum Neurofilament Light Chain Levels Among Patients With Clinically Isolted Syndrome Marzena Pedrini Australia
P-37 MS: MRI Study Association Between Distribution of Lesion with Clinical Disability in Indonesia Multiple Sclerosis Patients Salsabila Firdausia Indonesia
P-38 MS: MRI Study Lacune in Patients with Multiple Sclerosis Yexiang Zheng China
P-39 MS: MRI Study Different patterns of structural and functional alteration in neuromyelitis optica spectrum disorders and multiple sclerosis: a retrospective multi-center study Zhizheng Zhuo China
P-40 MS: MRI Study Diffusion Basis Spectrum Imaging Provides Insights into Multiple Sclerosis Anne Cross USA
P-41 MS: MRI Study Association between serum amyloid A and cortical volume in patients with multiple sclerosis: implications for the pathogenesis of brain atrophy Hiroaki Yokote Japan
P-42 MS: MRI Study Single Digit Modality Test (SDMT) Correlated with Brain Volume in Multiple Sclerosis Patients In Indonesia Dea Martasukma Gita Apsari Indonesia
P-43 MS: MRI Study Cortical volume, cortical thickness and cognitive performance: Comparison of an early real-world relapsing multiple sclerosis cohort and matched healthy controls Heidi Beadnall Australia
P-44 MS: MRI Study q-Space Myelin Map imaging for longitudinal analysis of remyelination in multiple sclerosis patients treated with dimethyl fumarate Kenji Kufukihara Japan
P-45 MS: MRI Study Measurement of Lateral Ventricle Enlargements of Multiple Sclerosis on MRI by Using “Automatic Segmentation Toolbox”: A Case Study Hakan Ekmekci Turkey
P-46 MS: MRI Study Hippocampus structural and functional alterations in MS and NMOSD Fenglian Zheng China
P-47 MS: MRI Study Fatigue Correlated With Corpus Callosum Volume In Multiple Sclerosis Patients In Indonesia Ilham Nurdin Indonesia
P-48 MS: MRI Study Cognitive Impairment is Related to Corpus Callosum and Thalamic damage in Chinese Multiple Sclerosis Patients Lin Zhao China
P-49 MS Treatment: Dimethyl Fumarate Safety and Tolerability of Dimethyl Fumarate in Japanese Real-world Clinical Setting Onizuka Yasuhiro Japan
P-50 MS Treatment: Dimethyl Fumarate Effectiveness of Dimethyl Fumarate in Japanese Patients with Multiple Sclerosis in Clinical Practice Onizuka Yasuhiro Japan
P-51 MS Treatment: Alemtuzumab Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) Hans-Peter Hartung Germany
P-52 MS Treatment: Alemtuzumab Alemtuzumab in Highly Active Multiple Sclerosis (HAMS): Experience with unlikely patients and unusual challenges Pramod Krishnan India
P-53 MS Treatment: Alemtuzumab Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CAREMS II Follow-up (TOPAZ Study) Giancarlo Comi Italy
P-54 MS Treatment: Alemtuzumab Long-term clinical outcomes of alemtuzumab in Korean patients with multiple sclerosis and predictor of disease activity despite alemtuzumab treatment Min Young  Lee Republic of Korea
P-55 MS Treatment: Cladribine Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies Giovannoni Gavin United Kingdom
P-56 MS Treatment: Cladribine Cladribine:a multicentre long term efficacy biomaker, Australian Study (CLOBAS) Jeannette Lechner-Scott Australia
P-57 MS Treatment: Cladribine Real world experience with Cladribine (Mavenclad) in MSBase registry Suzanne Hodgkinson Australia
P-58 MS Treatment: Cladribine Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis Suzanne Hodgkinson Australia
P-59 MS Treatment: Cladribine Increase of Naïve B Cells M2 Macrophages and Reduction of Memory B/T Cells During Immune Repopulation at 96 Weeks in CLARITY Assessed by Immune Cell Deconvolution Giovannoni Gavin United Kingdom
P-60 MS Treatment: Cladribine Interrogating The Influence Of The Multiple Sclerosis Modifying Drug Cladribine (2-Chlorodeoxyadenosine) Upon Primary Human Monocytes and Macrophages Tiago Medeiros Furquim Mendoca Netherlands
P-61 MS Treatment: Cladribine Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-Approval Data Stuart Cook USA
P-62 MS Treatment: Other drugs Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis [Encore] Bruce Taylor Australia
P-63 MS Treatment: Other drugs Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis [Encore] John Parratt Australia
P-64 Case Report: Other Allied Disorders Biomarker Changes in Relapsing Multiple Sclerosis (RMS) patients after B cell depletion with Ocrelizumab Anne Cross USA
P-65 MS Treatment: Other drugs Endpoints in the evaluation of anti-CD20 monoclonal antibodies in MS Thomas Berger Austria
P-66 MS Treatment: Other drugs Safety and Tolerability of Rituximab for NMO and MS: Treatment of Adults and Paediatrics patients in Singapore Siew Noi Janis Tye Singapore
P-67 MS Treatment: Other drugs Glucocorticoid receptor mutations and sensitivity to glucocorticoid in Chinese multiple sclerosis patients Tian Song China
P-68 MS Treatment: Other drugs Natalizumab Post-Marketing Surveillance: Interim Analysis Stratified by Baseline Disease Characteristics Onizuka Yasuhiro Japan
P-69 MS Treatment: Other drugs Real-world use of subcutaneous interferon β-1a in patients with relapsing multiple sclerosis Yesim Beckmann Turkey
P-70 Case Report: Other Allied Disorders Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomised, Placebo-controlled, Phase 2 Study Jurek Bojanowski USA
P-72 MS Treatment: Other drugs Integrating Chinese Medicine Improves Fatigue Associated with Multiple Sclerosis Alexander, Yuk Lun Lau China
P-73 NMOSD: Clinical Study Demographics and Clinical Characteristics of Patients with Neuromyelitis Optica in West Java, Indonesia Mimin Supriatin Indonesia
P-74 NMOSD: Clinical Study Treatment and Prognosis Analysis of Neuromyelitis Optica Spectrum Disorder Accompanied by Connective Tissue Disease: A Real-world Study in China Hexiang Yin China
P-75 NMOSD: Clinical Study Neuromyelitis optica spectrum disorders: The descriptive analysis of 48 patients Serkan Ozakbas Turkey
P-76 NMOSD: Clinical Study Neuromyelitis optica spectrum disorders: The evaluation of 66 patients followed by Istanbul Bilim University, Department of Neurology Burcu Altunrende Turkey
P-77 NMOSD: Clinical Study Identifying clinical characteristics which may help diagnose Aquaporin-4 antibody seropositive optic neuritis patients in Singapore Kevin Tan Singapore
P-78 NMOSD: Clinical Study Short Myelitis in Aquaporin 4 Seropositive Neuromyelitis Optica Spectrum Disorder Ju Vern Eu Malaysia
P-79 NMOSD: Clinical Study Onset of Aquaporin 4 Seropositive Neuromyelitis Optica Spectrum Disorder During Pregnancy and Postpartum Period Daniel, Yi Jie Wong Malaysia
P-80 NMOSD: Clinical Study Outcome of pregnancies following the neuromyelitis optica spectrum disorder symptom onset Su-Hyun Kim Republic of Korea
P-81 NMOSD: Clinical Study Bone Health in Neuromyelitis Optica: Bone Mineral Density and Fractures Young Nam Kwon Republic of Korea
P-82 NMOSD: Clinical Study Familial neuromyelitis optica spectrum disorder in Chinese population: a clinical profile and whole exome sequencing study Yanyu Chang China
P-83 NMOSD: Clinical Study Characterization of anti-neurofascin155 positive patients with optica neuromyelitis spectrum disorders Li Yang China
P-84 NMOSD: Clinical Study KCNMA1 is associated with the disability and transverse myelitis of neuromyelitis optica spectrum disorders: a genome-wide association study in Japanese. Takuya Matsushita Japan
P-85 NMOSD: Clinical Study Lhermitte Sign Due to Thoracic Spinal Cord Lesion in Neuromyelitis Optica Ryuhei Harada Japan
P-86 NMOSD: Clinical Study Brain MRI characteristics in NMOSD: a large multi-center retrospective study in China Yaou Liu China
P-87 NMOSD: Clinical Study Brain atrophy and ventricle enlargement in neuromyelitis optica spectrum disorders Decai Tian China
P-88 NMOSD: Clinical Study Distinction of Brainstem MRI Lesions Between MOG and AQP4 Antibody Associated Diseases Yuki Matsumoto Japan
P-89 NMOSD: Clinical Study Structural and functional MRI markers for cognitive impairment in neuromyelitis optica spectrum disorders Xinli Wang China
P-90 NMOSD: Laboratory Study Identification of a Distinct Exosomal microRNA Profile in Neuromyelitis Optica Spectrum Disorders by Next-generation Sequencing Chen Chen China
P-91 NMOSD: Laboratory Study WES Reveals the Major Genetic Contributors to Chinese Patients with NMOSD Seropositive for AQP4-IgG Xiaonan Zhong China
P-92 NMOSD: Laboratory Study Establishment and application of a new immunodot assay for detection of aquaporin 4 antibody (AQP4-Ab) Xiaobo Sun China
P-93 NMOSD: Laboratory Study Elevated Serum Glial Fibrillary Acidic Protein (sGFAP) is Associated With Increased Risk of Neuromyelitis Optica Spectrum Disorder Attacks in the N-Momentum Randomized, Masked, Placebo-Controlled Clinical Trial of Inebilizumab Orhan Aktas Germany
P-94 NMOSD: Laboratory Study Elevated cerebrospinal fluid – CRMP5 as a prognostic biomarker in NMOSD with AQP4-IgG Shuhei Nishiyama Japan
P-95 NMOSD: Laboratory Study Development of differential diagnostic marker using peptide microarray in central nervous system demyelinating disease in Korea Hye Lim Lee Republic of Korea
P-96 NMOSD: Laboratory Study Endothelial damage in patients with neuromyelitis optica spectrum disorder with aquaporin-4 IgG Hiroshi Kuroda Japan
P-97 NMOSD: Laboratory Study The Expression of IL-6 in The Central Nervous Tissue of Neuromyelitis Optica Spectrum Disorders Yoshiki Takai Japan
P-98 NMOSD: Treatment Sequential Intermittent Therapeutic Plasma Exchange As Induction And Maintenance Therapy In The Management Of Adult Patients With Neuromyelitis Optica Spectrum Disorder Jie Ping Schee Malaysia
P-99 NMOSD: Treatment Therapeutic Plasma Exchange (TPE) in Neuromyelitis Optica Spectrum Disorders (NMOSD) and related disorders in Resource Limited Settings: Outcomes in a Multi-ethnic Single Center Population Zhi Miin Ong Malaysia
P-100 NMOSD: Treatment Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD): a retrospective study Xindi Li China
P-101 NMOSD: Treatment A pilot, comparison study of the treatment in acute attack of neuromyelitis optica: Intravenous methylprednisolone (IVMP) with subsequent plasma exchange (PLEX) versus intravenous methylprednisolone combined with plasma exchange Thanapol Songthammawat Thailand
P-102 NMOSD: Treatment The N-MOmentum Study–A Randomised, Placebo-Controlled, Double-Blind Trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder: Randomised Controlled Period and Open-label Extension Results Ho Jin Kim Republic of Korea
P-103 NMOSD: Treatment Diagnosis, Severity and Recovery of Attacks in the N-MOmentum Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder Friedemann Paul Germany
P-104 NMOSD: Treatment Inebilizumab Reduces the Risk of Disability Progression in Neuromyelitis Optica Spectrum Disorder: Outcomes From the N-MOmentum Trial Kazuo Fujihara Japan
P-105 NMOSD: Treatment Characterization of B-cell Subset Changes Following Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) With Inebilizumab: Results From the N-MOmentum study Ho Jin Kim Republic of Korea
P-106 NMOSD: Treatment Long-term Safety and Efficacy of Eculizumab in Asian Patients With Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder Kazuo Fujihara Japan
P-107 NMOSD: Treatment Efficacy and Safety of Eculizumab in Asian Patients With Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder: Subgroup Analysis From the Phase 3 PREVENT Study Ho Jin Kim Republic of Korea
P-108 NMOSD: Treatment Efficacy of Satralizumab (SA237) in Subgroups of Patients in SAkuraSky: A Phase III Double-Blind, Placebo-Controlled, Add-On Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Takashi Yamamura Japan
P-109 NMOSD: Treatment Tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorders (TANGO): a head-to-head comparative study Fu-Dong Shi China
P-110 MOG Antibody Disease Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Similar to Multiple Sclerosis Toshiyuki Hayashi Japan
P-111 MOG Antibody Disease Detection of Serum Anti-Myelin Oligodendrocyte Glycoprotein Antibody in Malaysian Patients with Seronegative CNS Idiopathic Inflammatory Demyelinating Disorders Zhi miin Ong Malaysia
P-112 MOG Antibody Disease Myelin oligodendrocyte glycoprotein encephalomyelitis is associated with HLA subtypes in a Chinese paediatric-onset cohort Xiaobo Sun China
P-113 MOG Antibody Disease Serum Cytokine Profiles of Myelin Oligodendrocyte Glycoprotein Encephalomyelitis Young Nam Kwon Republic of Korea
P-114 MOG Antibody Disease Malignancy in MOG Encephalomyelitis: Prevalence, Description of Case, and Pathology Report Young Nam Kwon Republic of Korea
P-115 Animal Model The mechanism of Kv1.3 channel blocked on CD8+ T cells from EAE rats Yipeng Zhao China
P-116 Animal Model Teriflunomide maintains blood brain barrier in a animal model of multiple sclerosis Yipeng  Zhao China
P-117 Animal Model Caffeic acid phenethyl ester lessens experimental autoimmune encephalomyelitis through regulating T cell activity Yifan Zhou China
P-118 Case Report: MS Acute optic neuritis as an early sign of multiple sclerosis in patients with myasthenia gravis Jeong Bin Bong Republic of Korea
P-120 Case Report: MS Peripheral Nerve Demyelination With Conduction Block During A Relapse In Patients With Multiple Sclerosis: Report of Two Cases Eun Bin Cho Republic of Korea
P-121 Case Report: MS A case of multiple sclerosis with anti-N-methyl-D-aspartate receptor immunoglobulin G antibody Yao Zhang China
P-122 Case Report: MS A Case of Multiple Sclerosis with Early Escalation of Disease-Modifying Therapy Osamu Iwazaki Japan
P-123 Case Report: MS Splenic micro-abscesses secondary to oral Teriflunamide: A case report Rabani Remli Malaysia
P-124 Case Report: MS Hearing Loss in Association with Fingolimod Initiation in Paediatric-onset Multiple Sclerosis (POMS) Sing Yee Hoh Singapore
P-125 Case Report: MS Hair Loss Associated With Teriflunomide Treatment Sa-Yoon Kang Republic of Korea
P-126 Case Report: MS Case Study: Challenges of A Novel Therapy In Multiple Sclerosis Huey Tean Kok Malaysia
P-127 Case Report: NMOSD Neuromyelitis Optica Spectrum Disorder Patient Presenting With Bilateral Internuclear Ophthalmoplegia and Unilateral Peripheral Facial Paralysis Xueping Zheng China
P-128 Case Report: NMOSD Hyalinized Vessels Observed in Asymptomatic Optic Nerve in a Patient with Neuromyelitis Optica Spectrum Disorder Masashi Higashino Japan
P-129 Case Report: NMOSD Neuromyelitis Optica Spectrum Disorder with Upbeat Nystagmus and Intractable Vomiting as an Initially Presenting Symptom  Jae Myung Kim Republic of Korea
P-130 Case Report: NMOSD Delayed Diagnosis of Area Postrema Syndrome in an Elderly Patient with Dementia Kee Hong  Park Republic of Korea
P-131 Case Report: NMOSD Neuromyelitis optica spectrum disorders accompanying subdural hematoma Taek-Jun Lee Republic of Korea
P-132 Case Report: NMOSD Neuromyelitis Optica Spectrum Disorder Following Thymectomy in a Patient with Myasthenia Gravis Shin Yee Chey Malaysia
P-133 Case Report: NMOSD Severe Myelitis After a Long Interval of 20 Years From an Earlier Optic Neuritis Episode in Undiagnosed AQP4+ NMOSD Hui Jieh Tan Malaysia
P-134 Case Report: NMOSD Psoriasis induced by Rituximab in Neuromyelitis Optica Spectrum Disorders Stephen Cheng China
P-135 Case Report: Other Allied Disorders Anti-myelin oligodendrocyte glycoprotein antibody associated neuromyelitis optica spectrum disorder presenting unilateral homonymous hemianopia Kyong Jin Shin Republic of Korea
P-136 Case Report: Other Allied Disorders Clinical variability of MOG encephalomyelitis: A case report of leptomeningitis in MOG-IgG positive patient Young-Do Kim Republic of Korea
P-137 Case Report: Other Allied Disorders Two Japanese Cases of Anti-MOG Antibody-associated Encephalitis That Mimicked Neuro-Behçet’s Disease Juichi Fujimori Japan
P-138 Case Report: Other Allied Disorders Brain histopathological study and prognosis in two patients with MOG-antibody-associated demyelinating pseudotumor Yaqing Shu China
P-139 Case Report: Other Allied Disorders Cerebellar Lesions in a Patient with Anti-MOG Antibody-Associated Encephalomyelitis Takehito Ito Japan
P-140 Case Report: Other Allied Disorders Clinical variability of MOG encephalomyelitis: A case report of leptomeningitis in MOG-IgG positive patient Oh Jeeyoung Republic of Korea
P-141 Case Report: Other Allied Disorders Multifocal motor neuropathy and recurrent transverse myelitis associated with antibodies to myelin oligodendrocyte glycoprotein Kok Pin Yong Singapore
P-142 Case Report: Other Allied Disorders Tumefactive cystic demyelination in a child with MOG antibody recurrent disease Simon Ling Singapore
P-143 Case Report: Other Allied Disorders Myelin Oligodendrocytes Glycoprotein associated Disease Mimicking Acute Ischemic Stroke Byeol-A Yoon Republic of Korea
P-144 Case Report: Other Allied Disorders A Case of an Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease with Recurrent CNS Inflammation with Various Clinical Features  Woojun Kim Republic of Korea
P-145 Case Report: Other Allied Disorders Central nervous system immune-mediated demyelinating disease after allogeneic hematopoietic stem cell transplantation Seong-il Oh Republic of Korea
P-146 Case Report: Other Allied Disorders Longitudinal Extensive Transverse Myelitis by Spinal Cord Sarcoidosis mimicking Cervical Compressive Myelopathy Young-Do Kim Republic of Korea
P-147 Case Report: Other Allied Disorders A case of Guillain-Barre syndrome, optic neuritis and brain lesions after cytomegalovirus infection Hwang In Gun Republic of Korea
P-148 Case Report: Other Allied Disorders Tocilizumab treatment in refractory autoimmune GFAP astrocytopathy Zhang Chao China
P-149 Case Report: Other Allied Disorders The Curious Case of Three Antibodies: Paraneoplastic Encephalitis with NMDA, AMPA and PCA-1 Antibodies  Yihui Goh Singapore
P-150 Case Report: Other Allied Disorders Primary Central Nervous System Lymphoma Mimicking Tumefactive Multiple Sclerosis Byeol-A Yoon Republic of Korea
P-151 Case Report: Other Allied Disorders A Diffuse Large B Cell Lymphoma with Clinical and Imaging Characteristics of Neuromyelitis Optica Spectrum Disorder Woojun Kim Republic of Korea
P-152 Case Report: Other Allied Disorders Central Pontine Myelinolysis in a Patient with Hyperglycemia Jae Young An Republic of Korea
P-153 Case Report: Other Allied Disorders Spinal Dural Arteriovenous Fistula presenting as Area Postrema Syndrome Hazfadzila Bte Mohd Unit Malaysia
P-154 NMOSD: Treatment Efficacy and safety of satralizumab for relapse prevention in neuromyelitis optica spectrum disorder: a pooled analysis from two Phase 3 clinical trials Takashi Yamamura Japan